Risperidone Market Report 2026

The risperidone market size has grown strongly in recent years. It will grow from $7.7 billion in 2025 to $8.3 billion in 2026 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to increasing prevalence of schizophrenia and bipolar disorder, widespread clinical acceptance of atypical antipsychotics, availability of generic risperidone formulations, expansion of mental health treatment programs, improved psychiatric diagnosis rates.

The risperidone market size is expected to see strong growth in the next few years. It will grow to $11.13 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to increasing demand for long-acting antipsychotic injections, rising focus on personalized psychiatric care, expansion of community mental health services, growing use of digital mental health monitoring, increasing elderly patient population. Major trends in the forecast period include increasing preference for long-acting injectable formulations, rising use of extended-release tablets, growing focus on patient adherence solutions, expansion of pediatric and geriatric dosage forms, enhanced monitoring of treatment outcomes.

The rising incidence of mental health disorders is anticipated to drive expansion in the risperidone market. Mental health disorders encompass a broad spectrum of conditions that influence a person's mood, thinking, and behavior, leading to substantial distress or interference with everyday activities. This upsurge stems from elevated stress and contemporary lifestyle shifts that unsettle emotional equilibrium, sleep routines, and general mental health. Risperidone aids in controlling these disorders by regulating brain neurotransmitters, alleviating symptoms like agitation, hallucinations, and mood fluctuations, while fostering emotional steadiness. For instance, in March 2023, the Alzheimer's Association - a US-based nonprofit - reported that about 6.7 million Americans aged 65 and older had Alzheimer's dementia in 2023, with projections reaching 13.8 million by 2060. Thus, the growing prevalence of mental health disorders fuels risperidone market growth.

Major companies in the risperidone market are prioritizing innovative developments, like long-acting injectable versions, to enhance patient compliance and therapeutic results. These long-acting injectables are formulated to release risperidone steadily over time, supporting reduced dosing frequency with steady therapeutic benefits. For example, in January 2023, Luye Pharma Group Ltd., a pharmaceutical firm based in China, secured U.S. Food and Drug Administration (FDA) approval for Rykindo (risperidone), an extended-release injectable intended for treating schizophrenia in adults, and as monotherapy or adjunctive therapy alongside lithium or valproate for maintaining bipolar I disorder in adults. This biweekly intramuscular risperidone injection leverages Luye Pharma’s cutting-edge microsphere technology for prolonged, sustained-release delivery, helping sustain control of symptoms in schizophrenia and bipolar I disorder. The product provides quick onset for prompt symptom alleviation and enables rapid elimination post-discontinuation, offering clinicians more options to tailor treatments to individual patient requirements.

In January 2025, Lyndra Therapeutics Inc., a US-based clinical-stage biopharmaceutical company, collaborated with Thermo Fisher Scientific to advance clinical research and commercial manufacturing of its long-acting oral therapies. This collaboration seeks to revolutionize patient medication adherence by delivering the expertise and capacity needed to introduce innovative long-acting oral therapies, like weekly oral risperidone, to wide markets via dependable, scalable production and clinical trial assistance. Thermo Fisher Scientific Inc. is a US-based firm specializing in scientific and clinical research, including risperidone manufacturing.

Major companies operating in the risperidone market are Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Apotex Inc., Cipla Limited., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Zydus Cadila Healthcare Ltd, Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Natco Pharma Limited., Strides Pharma Science Limited., RPG Life Sciences Limited., Jubilant Cadista Pharmaceuticals Inc., ICROM S.p.A., Accord Healthcare Ltd., Ambica Pharma Machines Pvt. Ltd., Gonane Pharma Private Limited., Janssen Pharmaceuticals, LGM Pharma.

North America was the largest region in the risperidone market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the risperidone market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the risperidone market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the risperidone market by increasing costs of imported active pharmaceutical ingredients, excipients, injectable delivery systems, and pharmaceutical packaging materials. Pharmaceutical manufacturers and healthcare providers in North America and Europe are most affected due to reliance on global API supply chains, while Asia-Pacific faces pricing pressure on generic drug exports. These tariffs are contributing to higher drug production costs and supply chain complexity. However, they are also supporting domestic API manufacturing, local formulation facilities, and increased investment in regional pharmaceutical production.

The risperidone market research report is one of a series of new reports that provides risperidone market statistics, including risperidone industry global market size, regional shares, competitors with a risperidone market share, detailed risperidone market segments, market trends and opportunities, and any further data you may need to thrive in the risperidone industry. This risperidone market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Risperidone, an atypical antipsychotic drug, treats mental health conditions like schizophrenia, bipolar disorder, and irritability linked to autism. It functions by rebalancing key brain neurotransmitters, especially dopamine and serotonin, to enhance mood, thinking, and behavior.

The primary product forms of risperidone include tablets, oral solution, and injectable. Tablets represent an oral dosage form of risperidone, employed to treat mental health conditions like schizophrenia, bipolar disorder, and irritability linked to autism by regulating key neurotransmitters in the brain. It is given to various patient demographics, such as children, adults, and older adults. It serves multiple therapeutic purposes, including schizophrenia, bipolar disorder, autism, and additional uses. Distribution occurs via several channels, like hospital pharmacies, retail pharmacies, online pharmacies, and clinic pharmacies, reaching varied end users including hospitals, homecare settings, specialty clinics, ambulatory surgical centers, and others.

The risperidone market consists of sales of orally disintegrating tablets, oral syrups, injectable long-acting formulations, combination formulations, and extended-release tablets. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.